• Print Friendly, PDF & Email
  • Send to Kindle

Investors Pour Millions Into Israeli Cybersecurity Startups in July

A number of Israeli startups announced multi-million dollar funding successes in the last half of July, especially in the field of cybersecurity.

GuardiCore, the startup known for its internal data center security and breach detection, announced a $20 million Series B financing round led by existing investors. The Tel Aviv and San Francisco-based startup said it will use the funds to address growing demand for its security platform, invest in additional product research and development, expand its commercial reach through its global ecosystem and channel partners, and to fuel its overall sales and marketing efforts.

Skycure, a leader in mobile threat defense, announced a $16.5 million Series B investment, led by Foundation Capital and supported by all previous investors. The company – with offices in Silicon Valley, Tel Aviv and Ottawa, Canada – said it will use the new capital to expand its presence in Europe, the Middle East, Africa, and Asia Pacific; broaden its foothold with Global 1000 customers; and further develop its award-winning mobile threat defense platform.

Industrial cybersecurity company Indegy raised $12 million in a Series A round of financing led by Vertex Ventures Israel with participation from Silicon Valley-based Aspect Ventures, SBI Holdings of Japan, and previous investors. The company said it will use the funds to market its cybersecurity technology.

Meanwhile, startups Pixie Technology, Capriza, and Redis Labs also announced top funding rounds this past week for their technologies, as did biotech startup PamBio, which raised $7 million from a private investor for its groundbreaking stroke treatment. The Nazareth company’s treatment prevents bleeding and protects against brain damage.

“The solution we have developed, to prevent and stop bleeding, is based on an innovative understanding of the fibrinolysis pathway that is responsible for the breakdown of blood clots. In the future, this medication will allow treatment of additional bleeding disorders, which today do not have a safe and effective treatment, such as head injuries, bleeding in the digestive system, post-partum bleeding and other bleeding disorders,” said CEO Dr. Amos Ofer.

The new funding will be used for research.

(via Israel21c)

[Photo: Tomer Neuberg / Flash90 ]